Related Experiment Video
Updated: Apr 16, 2026
In Vitro Model of Coronary Angiogenesis
Published on: March 10, 2020
Relationship of fibroblast growth factor 23 and fetuin--A to coronary atherosclerosis
Fatih Akin1, Omer Celik2, Ibrahim Altun1
1Department of Cardiology, Muğla Sıtkı Kocman University School of Medicine, Muğla, Turkey.
Insights
Serum fibroblast growth factor 23 (FGF-23) and fetuin-A are elevated in patients with coronary artery disease (CAD). These markers, along with others, are independently associated with the presence of CAD, suggesting their potential as novel cardiovascular risk markers.
Area of Science:
- Biochemistry
- Cardiology
- Biomarkers
Background:
- Serum fibroblast growth factor 23 (FGF-23) and fetuin-A are known predictors of cardiovascular disease (CVD) morbidity and mortality.
- The study investigates the association between serum concentrations of FGF-23, fetuin-A, and coronary artery disease (CAD).
Purpose of the Study:
- To evaluate the relationship between coronary artery disease (CAD) and serum concentrations of FGF-23 and fetuin-A.
- To identify potential novel risk markers for cardiovascular disease.
Main Methods:
- A total of 383 subjects were included, all of whom underwent coronary computed tomography angiography (CCTA).
- Coronary artery disease (CAD) was detected in 208 patients via CCTA; the remaining patients had no detectable CAD.
Main Results:
- Serum FGF-23 and fetuin-A levels were significantly higher in CAD patients compared to non-CAD patients.
- Elevated FGF-23, fetuin-A, LDL-cholesterol, and uric acid were observed in non-diabetic CAD patients.
- Multivariate logistic regression identified age, hypertension, LDL-C, HDL-C, hs-CRP, uric acid, FGF-23, and fetuin-A as independent predictors of CAD presence.
Conclusions:
- FGF-23 and fetuin-A show a positive correlation with coronary atherosclerosis.
- While similar trends were observed in diabetic patients, they did not reach statistical significance.
- FGF-23 and fetuin-A may serve as novel risk markers for cardiovascular disease.
Background:
Serum fibroblast growth factor 23 (FGF-23) and fetuin-A are established predictors of morbidity and mortality due to cardiovascular disease. The objective of the present study is to evaluate the relationship between coronary artery disease (CAD) and serum concentrations of FGF-23 and fetuin-A.
Methods:
A total of 383 subjects who underwent coronary computed tomography angiography (CCTA) were included in the study. CCTA detected CAD in 208 patients; the rest of the patients had no detectable CAD.
Results:
Serum FGF-23 and fetuin-A levels were significantly increased in CAD patients compared to non-CAD patients (26.6±21.1pg/mL vs. 17.9±16.1pg/mL, p=0.001 and 826±350mg/L vs. 595±300mg/L, p<0.001, respectively). Serum FGF-23, fetuin-A, low-density lipoprotein (LDL)-cholesterol, and uric acid values were elevated in non-diabetic patients with CAD when compared to those without CAD. FGF-23, and fetuin-A were not significantly different in diabetic patients with CAD when compared to those without CAD. Using multivariate logistic regression analysis, we found that age, hypertension, LDL-Cholesterol, high-density lipoprotein (HDL)-Cholesterol, hs-CRP, uric acid, FGF-23 and fetuin-A levels were independently associated with the presence of CAD.
Conclusion:
FGF-23 and fetuin-A were positively correlated with coronary atherosclerosis Similar trends were seen among diabetic patients, but this did not reach statistical significance. FGF-23 and fetuin-A could be used as novel risk markers of cardiovascular disease.
